EWA
KLRS

EverSource Wealth Advisors’s Kalaris Therapeutics KLRS Stock Holding History

EverSource Wealth Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30
Closed -$241 – 4389
2025
Q1 		$241 Hold
30
– – ﹤0.01% 3662
2024
Q4 		$292 Hold
30
– – ﹤0.01% 3349
2024
Q3 		$562 Hold
30
– – ﹤0.01% 2847
2024
Q2 		$515 Sell
30
-28
-48% -$494 ﹤0.01% 2886
2024
Q1 		$1.06K Buy
+58
New +$946 ﹤0.01% 2559
2023
Q3 		– Sell
-7
Closed -$541 – 2683
2023
Q2 		$541 Buy
+7
New +$665 ﹤0.01% 2337

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EverSource Wealth Advisors's KLRS Position: Q2 2025 in Review

EverSource Wealth Advisors sold out of Kalaris Therapeutics (KLRS) in Q2 2025, closing a stake of 30 shares — an estimated $241 sold.

EverSource Wealth Advisors first reported a position in KLRS in Q2 2023 and held it in 6 quarters. The position peaked at $1.06K in Q1 2024. 30 funds tracked by Wall St. Rank hold KLRS as of Q2 2025.

  • EverSource Wealth Advisors reported no remaining Kalaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 30 Kalaris Therapeutics shares in Q2 2025, an estimated $241.
  • EverSource Wealth Advisors first reported a position in Kalaris Therapeutics in Q2 2023 and held it in 6 quarters.
  • EverSource Wealth Advisors's Kalaris Therapeutics position peaked at $1.06K in Q1 2024.
  • 30 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2025.

Based on EverSource Wealth Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.